Biogen Inc. ((BIIB)), Biogen ((CC:HTER)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biogen Inc. (BIIB) is currently conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Felzartamab in Adults With IgA Nephropathy (PREVAIL).’ The study aims to evaluate the effects of felzartamab on proteinuria in adults with Immunoglobulin A nephropathy (IgAN), a kidney disorder. The primary objective is to assess how felzartamab affects protein levels in urine over 36 weeks, alongside evaluating its impact on kidney function and safety.
The intervention involves administering intravenous doses of felzartamab, a drug designed to treat IgAN, compared to a placebo. The study is structured as a randomized, double-blind, placebo-controlled trial, ensuring neither participants nor researchers know who receives the treatment or placebo. The primary purpose is treatment-focused, with a parallel intervention model and quadruple masking.
The study began on May 8, 2025, and is currently recruiting participants. The primary completion date is projected for 2027, with the last update on July 1, 2025. These timelines are crucial for tracking progress and anticipating results.
This study could significantly impact Biogen’s market position, potentially enhancing investor confidence if results are positive. It also positions Biogen competitively in the nephrology treatment market, where advancements are keenly watched by investors and industry players.
The study is ongoing, with further details available on the ClinicalTrials portal.